Abstract: Provided herein are mertansine polypeptide conjugates useful in the treatment of cancer, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The methods provided herein are highly N-terminal selective and are capable of yielding N-terminal mertansine conjugated polypeptides with site selectivity of 99% or greater.

Abstract: Provided herein are mertansine polypeptide conjugates useful in the treatment of cancer, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The methods provided herein are highly N-terminal selective and are capable of yielding N-terminal mertansine conjugated polypeptides with site selectivity of 99% or greater.

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Abstract: The preparation of Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol with anti-tumor activity includes the following steps: 1) at normal temperature and under normal pressure, adding a Vitamin C solution to an aqueous solution of Pleurotus tuber-regium polysaccharides, and mixing uniformly; 2) adding dropwise a selenium dioxide solution or a selenite solution to the solution while mixing uniformly; and 3) adding water to the solution to a pre-determined volume, to obtain a Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol when the red color of the product is no longer deepened. The polysaccharides are used to control the particle size of nano-selenium, to obtain functionalized nano-elemental selenium with high anti-tumor activity and low toxicity. The anti-tumor activity of the biologically active molecule polysaccharides and the physiological effect of nano-selenium are combined, and a synergistic anti-tumor effect is achieved.

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Abstract: The preparation of Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol with anti-tumor activity includes the following steps: 1) at normal temperature and under normal pressure, adding a Vitamin C solution to an aqueous solution of Pleurotus tuber-regium polysaccharides, and mixing uniformly; 2) adding dropwise a selenium dioxide solution or a selenite solution to the solution while mixing uniformly; and 3) adding water to the solution to a pre-determined volume, to obtain a Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol when the red color of the product is no longer deepened. The polysaccharides are used to control the particle size of nano-selenium, to obtain functionalized nano-elemental selenium with high anti-tumor activity and low toxicity. The anti-tumor activity of the biologically active molecule polysaccharides and the physiological effect of nano-selenium are combined, and a synergistic anti-tumor effect is achieved.

Abstract: Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrins as catalyst provides high trans-selectivities (i.e., trans-:cis-epoxide ratio). A diversity of cycloalkenes bearing different allylic substituents are shown to be efficiently epoxidized to afford the corresponding trans-epoxides with excellent trans-selectivities (up to >98%) and good yields (up to 99%). Acyclic allylic alkenes bearing different allylic substituents are efficiently epoxidized to afford the corresponding erythro-epoxides with good erythro-selectivities. The metalloporphyrin-catalyzed reactions exhibit up to 20 times higher trans-selectivities than the conventional method using m-chloroperoxybenzoic acid as oxidant.

Abstract: Diastereoselective epoxidation of allylically substituted alkenes using metalloporphyrins as catalyst provides high trans-selectivities (i.e., trans-:cis-epoxide ratio). A diversity of cycloalkenes bearing different allylic substituents are shown to be efficiently epoxidized to afford the corresponding trans-epoxides with excellent trans-selectivities (up to >98%) and good yields (up to 99%). Acyclic allylic alkenes bearing different allylic substituents are efficiently epoxidized to afford the corresponding erythro-epoxides with good erythro-selectivities. The metalloporphyrin-catalyzed reactions exhibit up to 20 times higher trans-selectivities than the conventional method using m-chloroperoxybenzoic acid as oxidant.

Abstract: This invention provides a collapsible and foldable structure suitable for use by infants as a play area for both indoor and, in particular, outdoor use. The invention incorporates the use of flexible loops of material which may be deformed into a plurality of concentrated loops when in the collapsed state for easy transportation and storage. A sheet of material may be attached on which the infant may lie and includes a raised member extending over the sheet to which a further cover may be attached and/or used for hanging items for the child's amusement or entertainment.

Abstract: Methods for effecting epoxidation of olefinic compounds using cyclic ketone catalysts is provided. In particular, catalytic asymmetric epoxidation of unfunctionalized olefins, e.g., trans-olefins and trisubstituted olefins using novel cyclic ketones possessing C.sub.2 symmetric chiral elements is provided.